Akinyanju O O
Clin Lab Haematol. 1985;7(2):133-42. doi: 10.1111/j.1365-2257.1985.tb00017.x.
In order to determine the contribution of neutrophil malfunction to the phenomenon of enhanced susceptibility of sickle cell disease patients to bacterial infection, the in-vivo neutrophil migration capacity in 23 sickle cell patients and in 14 normal controls; and the neutrophil reduction of nitroblue tetrazolium dye in 74 sickle cell patients and in 78 normal controls were studied. Secondarily the usefulness of the NBT test in distinguishing between osteomyelitis and uncomplicated bone pain was examined. No impairment of neutrophil migratory capacity was evident as no significant difference was observed between the mean migrated neutrophil count in the sickle cell subjects (1.99 X 10(9)/1) and that in normal controls (2.08 X 10(9)/1). The mean NBT scores were 19.9 +/- 8.9% in non-infected controls and 41.3 +/- 14.6% in infected controls (P less than 0.001). In sickle cell disease they were 23.6 +/- 6% in steady state subjects, 29.2 +/- 16.4% in sterile painful crises, 42.9 +/- 15% in non-osteomyelitic bacterial infection (P less than 0.001) and 18.9 +/- 4.2% during osteomyelitis. Thus all sickle cell subjects apart from those with osteomyelitis showed significant increases in the NBT scores during bacterial infection. The low score in sickle cell osteomyelitis is possibly associated with a relative neutrophil phagocytic defect which requires further elucidation. The NBT test was not useful in distinguishing uncomplicated painful crisis from early osteomyelitis in sickle cell disease.
为了确定中性粒细胞功能异常对镰状细胞病患者易发生细菌感染现象的影响,研究了23例镰状细胞病患者和14例正常对照者体内中性粒细胞的迁移能力;以及74例镰状细胞病患者和78例正常对照者中性粒细胞对硝基蓝四氮唑染料的还原能力。其次,研究了硝基蓝四氮唑试验在鉴别骨髓炎和单纯性骨痛方面的实用性。未发现中性粒细胞迁移能力受损,因为镰状细胞病患者的平均迁移中性粒细胞计数(1.99×10⁹/升)与正常对照者(2.08×10⁹/升)之间未观察到显著差异。非感染对照组的平均硝基蓝四氮唑评分是19.9±8.9%,感染对照组是41.3±14.6%(P<0.001)。在镰状细胞病患者中,病情稳定者的评分是23.6±6%,无菌性疼痛危象者是29.2±16.4%,非骨髓炎性细菌感染者是42.9±15%(P<0.001),骨髓炎患者是18.9±4.2%。因此,除骨髓炎患者外,所有镰状细胞病患者在细菌感染期间硝基蓝四氮唑评分均显著升高。镰状细胞性骨髓炎评分低可能与相对的中性粒细胞吞噬缺陷有关,这需要进一步阐明。硝基蓝四氮唑试验在鉴别镰状细胞病的单纯性疼痛危象和早期骨髓炎方面没有帮助。